Bluebird Bio Announces Completion Of Acquisition By Carlyle And SK Capital

Published on 06/02/2025 at 09:03

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about bluebird bio, Inc.

Bluebird Bio, Inc. Announces Management Changes	Jul. 01	CI
Carlyle, SK Capital Partners Close Bluebird Bio Acquisition	Jun. 02	MT
Bluebird Bio Announces Completion Of Acquisition By Carlyle And SK Capital	Jun. 02	RE
Bluebird bio, Inc.(NasdaqGS:BLUE) dropped from NASDAQ Composite Index	Jun. 01	CI
Sector Update: Health Care Stocks Advance Late Afternoon	May. 30	MT
Sector Update: Health Care Stocks Rise in Afternoon Trading	May. 30	MT
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer	May. 30	RE
Carlyle-Led Group Closes Tender Offer for Bluebird Bio	May. 30	MT
SK Capital Partners, LP and The Carlyle Group Inc. (NasdaqGS:CG) completed the acquisition of bluebird bio, Inc..	May. 28	CI
Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	May. 26	CI
PepGen Inc. Appoints Kasra Kasraian as Chief Technology Officer	May. 20	CI
Carlyle, SK Capital Partners And Bluebird Bio Provide Updated Tender Instructions	May. 16	RE
Bluebird bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 14	CI
Deals of the day-Mergers and acquisitions	May. 14	RE
Top Midday Gainers	May. 14	MT
Bluebird bio, Carlyle, SK Capital Revise Acquisition Deal to Add New Cash Option	May. 14	MT
Deals of the day-Mergers and acquisitions	May. 14	RE
Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital	May. 14	RE
Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital	May. 14	RE
Carlyle says Bluebird stockholders can elect $3 per share plus cvr or $5 per share	May. 14	RE
Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital	May. 14	RE
Bluebird bio, Inc.(NasdaqGS:BLUE) dropped from S&P TMI Index	May. 12	CI
Bluebird bio, Inc.(NasdaqGS:BLUE) dropped from S&P Global BMI Index	May. 12	CI
European Commission Green-lights SK Capital, Carlyle's Purchase of Bluebird Bio	May. 06	MT
Bluebird bio, Carlyle-SK Deal Clears Regulatory Hurdles	May. 06	MT